Welcome to Medications.com

New Drug Application Submitted to FDA for Centrally Acting ... - netPR.pl (komunikaty prasowe)

The US clinical development program includes two double blind phase 3 multi-center studies vs. oxycodone IR that explored the efficacy and safety of ...

http://media.netpr.pl/notatka_923... | Posted: Fri Jan 25 02:26:27 -0500 2008




© 2002-2007, Skylabs Inc.  |  About Us  |  Disclaimer/Terms of Use  |  Advertise  |  Contact Us  |  Site Map  |  Developed by: W3matter.com | Sleep Apnea